Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.

Oncology research - 2 Nov 2017

Vetma Vesna, Rožanc Jan, Charles Emilie M, Hellwig Christian T, Alexopoulos Leonidas G, Rehm Markus

Abstract excerpt

Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is currently being tested in phase II clinical trials. We herein aimed to investigate the antitumor efficacy of dacarbazine in vitro, both as a single agent and in combination with birinapant, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Dacarbazine

Share to Dipeptides

Share to Indoles

Share to Melanoma

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28337955
DOI: 10.3727/096504017X14897145996933
PMCID: PMC7841063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.PMID 28337955Read ↗

A cell-based high-throughput screen to identify synergistic TRAIL sensitizersSemantic proximity Read ↗

In Vitro Evaluation of the Potential Synergistic Interactions Between Apigenin and Bortezomib in U266 Multiple Myeloma CellsSemantic proximity Read ↗

The MAPK pathway as an apoptosis enhancer in melanomaSemantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic BirinapantSemantic proximity Read ↗

Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.Semantic proximity Read ↗

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Semantic proximity Read ↗

Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells.Semantic proximity Read ↗

Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A KinaseSemantic proximity Read ↗

A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.Semantic proximity Read ↗

Antitumor activity of sequence‐specific alkylating agents: Pyrolle‐imidazole CBI conjugates with indole linkerSemantic proximity Read ↗

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.